VTRS catalyst calendar

Viatris Inc

Upcoming catalysts
7
Cash runway
Cash generating
Cash & investments
$927M
Phase 3 programs
5

Viatris Inc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome on October 15, 2026. There are 7 upcoming events on record.

Viatris Inc generates cash from operations, so a burn-based runway figure does not apply.

Across 18 concluded trials, 94% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome Trial Milestone Phase 1
November 5, 2026 est. Next quarterly earnings (projected) Earnings —
December 31, 2026 A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus Trial Milestone Phase 3
March 31, 2027 A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus Trial Milestone Phase 3
July 15, 2027 Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Trial Milestone Phase 3
August 15, 2029 A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment Trial Milestone Phase 3
September 15, 2032 Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus Trial Milestone Phase 3

Track VTRS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open VTRS in the tracker

Recent history

DateEventTypePhase
October 8, 2026 8-K filed: Material agreement, Other event Corporate —
August 6, 2026 Quarterly results filed (8-K) Earnings —
July 1, 2026 8-K filed: Material agreement Corporate —
June 18, 2026 8-K filed: Material agreement Corporate —
June 15, 2026 8-K filed: Other event Filing —
May 7, 2026 Quarterly results filed (8-K) Earnings —
May 4, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
March 18, 2026 A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants Trial Milestone Phase 1
February 26, 2026 Quarterly results filed (8-K) Earnings —
February 3, 2026 8-K filed: Leadership change Corporate —
December 8, 2025 8-K filed: Reg FD disclosure Filing —
December 5, 2025 8-K/A filed: Leadership change Corporate —
November 6, 2025 Quarterly results filed (8-K) Earnings —
November 5, 2025 A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants Trial Milestone Phase 1
October 24, 2025 8-K filed: Other event Filing —
August 7, 2025 Quarterly results filed (8-K) Earnings —
August 5, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
May 8, 2025 Quarterly results filed (8-K) Earnings —
May 5, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
August 18, 2024 A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod Trial Milestone Phase 1
July 27, 2023 The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics Trial Milestone Phase 1
September 14, 2021 To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men. Trial Milestone Phase 1
August 31, 2021 Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Trial Milestone Phase 2
December 19, 2020 A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects Trial Milestone Phase 1
October 23, 2020 The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics Trial Milestone Phase 1
October 29, 2019 Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects Trial Milestone Phase 1
May 20, 2019 A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects Trial Milestone Phase 1
February 12, 2019 A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects Trial Milestone Phase 1
November 10, 2018 A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack Trial Milestone Phase 2
August 18, 2018 A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.